Plus: Meme mania returns ahead of big tech earnings; ASIC chief to warn banks and boards over risky AI use; Microsoft names ...

Sanofi acquires Vicebio for $1.15 billion, adding a next-gen RSV-hMPV vaccine and ‘Molecular Clamp' tech to strengthen its respiratory vaccine pipeline.

Sanofi is acquiring UK biotechnology company Vicebio for up to US$1.6 billion ($2.4 billion) in the largest deal involving a ...

French pharmaceuticals company Sanofi said on Tuesday it would acquire British private biotechnology firm Vicebio for a total ...

The acquisition, which will give Sanofi a combination vaccine for respiratory syncytial virus and human metapneumovirus, ...

Sanofi has announced that it will be expanding its respiratory vaccines pipeline by acquiring UK-based Vicebio for up to ...

French pharmaceutical and healthcare company Sanofi has agreed to buy the British biotechnology firm Vicebio for up to $1.6bn ...

French pharmaceuticals giant Sanofi has agreed to acquire privately-owned British biotech firm, Vicebio, in a deal worth up ...

Sanofi has moved to bolster its vaccines business by reaching a deal to buy London, UK-based biotech Vicebio, which was ...

Sanofi has struck a deal to buy Vicebio for $1.15 billion upfront, securing preclin | Sanofi has struck a deal to buy Vicebio ...

Sanofi will acquire Vicebio for USD 1.15 bn, gaining RSV/hMPV vaccine candidates plus the Molecular Clamp platform for refrigeration‑stable combination vaccines. Deal expected by Q4 2025, supporting ...

PARIS] Sanofi agreed to buy UK biotech Vicebio for as much as US$1.6 billion, gaining experimental vaccines and a technology ...